Martin Dreyling is Professor of Medicine and head of the lymphoma programme at the Department of Medicine III, LMU Hospital Munich. He studied at the Universities of Düsseldorf, Giessen, Tübingen and Würzburg, and completed his clinical training at the Universities of Bonn, Münster, Göttingen and Munich. In addition, he was visiting scientist at the University of Chicago.

His scientific focus is on the molecular basis of malignant transformation, cell cycle dysregulation and secondary genetic alterations as well as biological prognostic factors in malignant lymphoma. He is also interested in innovative therapeutic approaches, including molecular targeted approaches like inhibitors of the B-cell receptor pathway and immunological approaches.

Prof. Dreyling is coordinator of the European MCL Network and president of the German Lymphoma Alliance as well as EHA executive board member. He has co-authored numerous scientific papers and abstracts in international peer-reviewed journals.